Beneficial Effects of Fingolimod in Alzheimer's Disease

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.
Post Reply
User avatar
Petr75
Family Elder
Posts: 496
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

Beneficial Effects of Fingolimod in Alzheimer's Disease

Post by Petr75 » Thu Sep 26, 2019 3:19 am

2019 Sep
Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Greece
Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential
https://www.ncbi.nlm.nih.gov/pubmed/31313064

Abstract

Alzheimer's disease (AD), the most common cause of dementia remains of unclear etiology with current pharmacological therapies failing to halt disease progression. Several pathophysiological mechanisms have been implicated in AD pathogenesis including amyloid-β protein (Aβ) accumulation, tau hyperphosphorylation, neuroinflammation and alterations in bioactive lipid metabolism. Sphingolipids, such as sphingosine-1-phosphate (S1P) and intracellular ceramide/S1P balance are highly implicated in central nervous system physiology as well as in AD pathogenesis. FTY720/Fingolimod, a structural sphingosine analog and S1P receptor (S1PR) modulator that is currently used in the treatment of relapsing-remitting multiple sclerosis (RRMS) has been shown to exert beneficial effects on AD progression. Recent in vitro and in vivo evidence indicate that fingolimod may suppress Aβ secretion and deposition, inhibit apoptosis and enhance brain-derived neurotrophic factor (BDNF) production. Furthermore, it regulates neuroinflammation, protects against N-methyl-D-aspartate (NMDA)-excitotoxicity and modulates receptor for advanced glycation end products signaling axis that is highly implicated in AD pathogenesis. This review discusses the underlying molecular mechanisms of the emerging neuroprotective role of fingolimod in AD and its therapeutic potential, aiming to shed more light on AD pathogenesis as well as direct future treatment strategies.

User avatar
Petr75
Family Elder
Posts: 496
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

Re: Beneficial Effects of Fingolimod in Alzheimer's Disease

Post by Petr75 » Thu Oct 03, 2019 10:54 am

2019 Jul 29
Department of Veterans Affairs, VA Boston Healthcare System, Boston
Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6662857/

Abstract

Lipid metabolism is abnormal in Alzheimer's disease (AD) brain leading to ceramide and sphingosine accumulation and reduced levels of brain sphingosine-1-phosphate (S1P). We hypothesize that changes in S1P signaling are central to the inflammatory and immune-pathogenesis of AD and the therapeutic benefits of fingolimod, a structural analog of sphingosine that is FDA approved for the treatment of multiple sclerosis. We recently reported that the neuroprotective effects of fingolimod in 5xFAD transgenic AD mice treated from 1-3 months of age were greater at 1 mg/kg/day than at 5 mg/kg/day. Here we performed a dose-response study using fingolimod from 0.03 to 1 mg/kg/day in 5xFAD mice treated from 1-8 months of age. At 1 mg/kg/day, fingolimod decreased both peripheral blood lymphocyte counts and brain Aβ levels, but at the lowest dose tested (0.03 mg/kg/day), we detected improved memory, decreased activation of brain microglia and astrocytes, and restored hippocampal levels of GABA and glycerophosphocholine with no effect on circulating lymphocyte counts. These findings suggests that, unlike the case in multiple sclerosis, fingolimod may potentially have therapeutic benefits in AD at low doses that do not affect peripheral lymphocyte function.

Post Reply
  • Similar Topics
    Replies
    Views
    Last post